These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 29753748)

  • 1. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
    Johnson MW; Griffiths RR; Hendricks PS; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():143-166. PubMed ID: 29753748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations in assessing the abuse potential of psychedelics during drug development.
    Calderon SN; Bonson KR; Reissig CJ; Lloyd JM; Galati S; Chiapperino D
    Neuropharmacology; 2023 Feb; 224():109352. PubMed ID: 36455646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.
    Henningfield JE; Coe MA; Griffiths RR; Belouin SJ; Berger A; Coker AR; Comer SD; Heal DJ; Hendricks PS; Nichols CD; Sapienza F; Vocci FJ; Zia FZ
    Neuropharmacology; 2022 Nov; 218():109220. PubMed ID: 35987353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A regulatory perspective on the evaluation of hallucinogen drugs for human use.
    Calderon SN; Hunt J; Klein M
    Neuropharmacology; 2018 Nov; 142():135-142. PubMed ID: 29180224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.
    Heal DJ; Gosden J; Smith SL
    Neuropharmacology; 2018 Nov; 142():89-115. PubMed ID: 29427652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Therapeutic Effects of Psilocybin.
    Johnson MW; Griffiths RR
    Neurotherapeutics; 2017 Jul; 14(3):734-740. PubMed ID: 28585222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective.
    Henningfield JE; Ashworth J; Heal DJ; Smith SL
    J Psychopharmacol; 2023 Jan; 37(1):33-44. PubMed ID: 36588452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.
    Thomas K; Malcolm B; Lastra D
    J Psychoactive Drugs; 2017; 49(5):446-455. PubMed ID: 28481178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review.
    Kaminski D; Reinert JP
    Ann Pharmacother; 2024 Aug; 58(8):811-826. PubMed ID: 37902038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
    Bogenschutz MP; Forcehimes AA; Pommy JA; Wilcox CE; Barbosa PC; Strassman RJ
    J Psychopharmacol; 2015 Mar; 29(3):289-99. PubMed ID: 25586396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Psilocybin-Assisted Treatment of Depression, Anxiety and Substance use Disorders: Neurobiological Basis and Clinical Application].
    Lasch A; Schweikert T; Dora E; Kolb T; Schurig HL; Walther A
    Fortschr Neurol Psychiatr; 2024 Jun; 92(6):230-245. PubMed ID: 37207669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacology of psilocybin.
    Passie T; Seifert J; Schneider U; Emrich HM
    Addict Biol; 2002 Oct; 7(4):357-64. PubMed ID: 14578010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psilocybin history, action and reaction: A narrative clinical review.
    Sharma P; Nguyen QA; Matthews SJ; Carpenter E; Mathews DB; Patten CA; Hammond CJ
    J Psychopharmacol; 2023 Sep; 37(9):849-865. PubMed ID: 37650489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
    Grob CS; Danforth AL; Chopra GS; Hagerty M; McKay CR; Halberstadt AL; Greer GR
    Arch Gen Psychiatry; 2011 Jan; 68(1):71-8. PubMed ID: 20819978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.